GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » ROIC %
中文

Design Therapeutics (Design Therapeutics) ROIC % : -607.94% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Design Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -607.94%.

As of today (2024-04-24), Design Therapeutics's WACC % is 15.29%. Design Therapeutics's ROIC % is -831.30% (calculated using TTM income statement data). Design Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Design Therapeutics ROIC % Historical Data

The historical data trend for Design Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics ROIC % Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-189.29 -897.63 -832.21 -752.54 -781.51

Design Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -791.47 -938.54 -1,067.74 -802.43 -607.94

Competitive Comparison of Design Therapeutics's ROIC %

For the Biotechnology subindustry, Design Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Design Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's ROIC % falls into.



Design Therapeutics ROIC % Calculation

Design Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-78.19 * ( 1 - 0% )/( (10.201 + 9.809)/ 2 )
=-78.19/10.005
=-781.51 %

where

Design Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-60.484 * ( 1 - 0% )/( (10.089 + 9.809)/ 2 )
=-60.484/9.949
=-607.94 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Design Therapeutics  (NAS:DSGN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Design Therapeutics's WACC % is 15.29%. Design Therapeutics's ROIC % is -831.30% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Design Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Design Therapeutics (Design Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Executives
Rodney W Lappe director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William director C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Joao Md Siffert director, officer: President and CEO 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George director, 10 percent owner 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu director, 10 percent owner C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess officer: Chief Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio officer: Principal Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Pratik Shah director, officer: Executive Chairperson 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Sean Jeffries officer: Chief Operating Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker officer: Vice President, Finance C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Aseem Z. Ansari 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011

Design Therapeutics (Design Therapeutics) Headlines

From GuruFocus